Anthropic demonstrated that Claude AI can autonomously design novel proteins at scale: 14 of 15 target designs were validated by external labs, with success rates 22–35% vs. industry standard 10–15%. The system completed de novo protein-binding design in 48 hours—work that typically requires months of human expert coordination across computational and structural biology teams. This showcases AI-driven acceleration in drug discovery and biotech R&D, with implications for Thai biotech startups and research institutions exploring AI-assisted molecular design.